Merck's Muted Gains and 122nd-Ranked Volume Highlight Regulatory Risks Amid Alzheimer's R&D Progress

Merck (MRK) closed on September 16, 2025, with a 0.09% gain, trading on a volume of $0.81 billion, ranking 122nd in market activity for the day. The stock’s muted performance reflected a broader market consolidation phase, with investors parsing mixed signals from the biopharmaceutical sector amid regulatory and pricing pressures.

Recent developments highlighted regulatory scrutiny as a key risk factor. A pending U.S. Department of Justice review of Merck’s proposed $23 billion acquisition of a mid-sized biotech firm raised concerns about antitrust implications. Analysts noted that regulatory delays could impact near-term guidance, though the company’s core oncology pipeline remains robust.

Meanwhile, Merck’s R&D disclosures in mid-September pointed to progress in its experimental Alzheimer’s drug trials, with interim data showing a 30% reduction in cognitive decline markers. However, market participants remained cautious, citing the high attrition rate in neurodegenerative disease therapies.

To run this back-test accurately I need to clarify a couple of points: 1. Market universe – Are we looking at U.S. listed equities only (NYSE + NASDAQ), or a different market/universe? 2. Trade price – Should each day’s basket be bought at that day’s open and sold at the same day’s close, or bought at today’s close and sold at the next day’s close? (Either is common for an intraday-vs-overnight test.) 3. Costs – Do you want to include transaction costs/slippage, or treat trades as frictionless? Once I have this information I can set up the data retrieval and run the back-test.